多沙唑嗪治疗轻中度高血压疗效和安全性的临床研究

目的 评价新一代α_1受体拮抗剂甲磺酸多沙唑嗪的降压疗效及安全性,并与盐酸特拉唑嗪相比较。方法 采用随机分组平行对照方法,将226例轻、中度高血压患者分成两组:多沙唑嗪组(111例)口服甲磺酸多沙唑嗪2mg/d;盐酸特拉唑嗪组(115例)口服盐酸特拉唑嗪2mg/d。疗程8周。每两周一次上午监测诊室谷值坐位舒张压、心率,立位舒张压,并观察不良反应。用药前及治疗第8周后检测血液生化指标。第2周末谷值坐位舒张压仍大于90mmHg者加量至4mg/d,第4周末谷值坐位舒张压仍大于90mmHg者加量至6mg/d,第6周末谷值坐位舒张压仍大于90mmHg者,终止试验,改服其它药物。结果 治疗8周后甲磺酸多沙唑嗪组与盐酸特拉唑嗪组治疗有效反应率分别为74.77％和76.52％,(P>0.05);治疗后两组平均谷值坐位舒张压均有明显降低(P<0.05)。两组均无严重不良反应发生。结论 甲磺酸多沙唑嗪与盐酸特拉唑嗪降压疗效相似,不良反应发生率均较低,是一种安全、有效的治疗轻、中度原发性高血压的药物。

The efficacy and the safety of doxazosin in treatment of hypertension

Objective To evaluate the efficacy and safety of doxazosin in the treatment of hypertension. Methods Two hundred and twenty patients with mild or moderate hypertension were randomly assigned to receive doxazosin 2 - 6mg/d or terazosin 2 -6mg/d for 8 weeks. A trough sitting DBP/SBP and HR were measured before and biweekly after medication. Adverse effects were recorded. Blood biochemical tests were studied before and after taking drugs. Doxazosin and Terazosin were added to 4 mg/d if DBP was > 90 mmHg after 2 weeks and to 6 mg/d after 4 weeks. Results After 8 weeks the total response rate was 74.77% in doxazosin group and 76.52% in terazosin group (P>0.05) .A trough sitting DBP/SBP was effectively reduced after medication. No sevius adverse effects were recorded. Conclusion Both doxazosin and terazosin are effective and safe drugs to decrease high blood pressure.